Ray’s Vitamins – FDA Warning Letter, Apr 1, 2026

In a Warning Letter dated April 24, 2026, the U.S. Food and Drug Administration (FDA) notified Ray’s Vitamins of significant legal violations discovered during a review of their website in April 2026. The primary issue involves the product “Yeicob Ácido Hialurónico,” which laboratory analysis confirmed contains two undeclared pharmaceutical ingredients: diclofenac, a non-steroidal anti-inflammatory drug (NSAID), and dexamethasone, a corticosteroid. These hidden ingredients pose severe health risks to consumers, including potential heart attacks, gastrointestinal bleeding, and impaired immune function. Under the Federal Food, Drug, and Cosmetic Act, the FDA determined that “Yeicob Ácido Hialurónico” is both an unapproved new drug and a misbranded drug. Although marketed as a dietary supplement, the product’s claims to treat arthritis and joint pain—combined with its undisclosed pharmaceutical content—place it outside the legal definition of a supplement. Furthermore, the labeling is considered false and misleading because it fails to list the active drug ingredients. The FDA also highlighted safety concerns regarding other products sold by the firm, such as “RM Joe” and “RMSOL GRACIAN.” Ray’s Vitamins is required to investigate these violations and ensure all products comply with federal safety regulations. The company must provide a written response to the FDA within 15 working days detailing the corrective actions taken to address these issues and prevent their recurrence. Failure to comply may lead to legal consequences, such as product seizures or court injunctions.